ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2064

Quantifying Cutaneous Dermatomyositis: A Novel 3D Image-based Approach
Abstract Number: 1972

Quantifying Sjogren’s Disease Burden: UHFUS Evaluation of the Number and Severity of Involved Exocrine Gland
Abstract Number: 2477

Quantifying Tissue Microstructural Changes in Scleroderma Skin Using a Novel, Point-of-care, High-frequency-ultrasound Instrument
Abstract Number: 0738

Quantitative Vascular US Has Additional Diagnostic and Prognostic Value in GCA
Abstract Number: 0914

RAB19 and Azathioprine-Associated Pancreatic Injury in Patients Taking Azathioprine
Abstract Number: 2313

Race and Ethnicity as Predictors of Diagnostic Delay in Psoriatic Arthritis and Axial Spondyloarthritis
Abstract Number: 0176

Race-Based Differences in Immune Responses Following an Episode of Acute Low Back Pain Among Those Who Develop Chronic LBP and Those Who Do Not
Abstract Number: 2017

Race, Ethnicity, and Rheumatology Care Predict Long-term Urate-Lowering Treatment Persistence Following a Treat-to-Target Intervention in a Large, Multicenter Randomized Trial
Abstract Number: 1873

Race/Ethnicity and Household Income at the County Level Interacts with the Association of Urbanicity and Lupus Nephritis Mortality
Abstract Number: 1926

Race/ethnicity Is Associated with Disease Severity in Pediatric Patients with ANCA-associated Vasculitis Hospitalized in the United States
Abstract Number: 1914

Racial and Ethnic Differences in the Prevalence of Disease Features in Systemic Sclerosis
Abstract Number: 1924

Racial and Gender Disparities in Psoriatic Arthritis Clinical Trials
Abstract Number: 0189

Racial Discrimination Among African American Women with and Without Systemic Lupus Erythematosus (SLE)
Abstract Number: 1909

Racial Disparities in Ocular Complications of Systemic Rheumatic Diseases: A Retrospective Cross-Sectional Study
Abstract Number: 0329

Racial, Ethnic, Sex, and Geographical Diversity in Myositis Clinical Trials: Future Steps for Equitable Representation by the MIHRA Global Equity and Clinical Trial Readiness Cores

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].